Shah, S. Ali et al. published their research in Journal of Physiology and Pharmacology in 2020 | CAS: 1222780-33-7

1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7) belongs to piperidine derivatives. The piperidine structural motif is present in numerous natural alkaloids. These include piperine, which gives black pepper its spicy taste. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising α-glucosidase inhibitors. The former are analogs of DNJ with an improved α-glucosidase inhibitory profile than that of DNJ. Boisson et al.Name: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea

Inhibition of soluble epoxide hydrolase offers protection against fructose-induced diabetes and related metabolic complications in rats was written by Shah, S. Ali;Mehmood, M. H.;Khan, M.;Bukhari, I. Ali;Alorainey, B. I.;Vohra, F.. And the article was included in Journal of Physiology and Pharmacology in 2020.Name: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea The following contents are mentioned in the article:

Stabilization of epoxyeicosatrienoic acids (EETs) levels via soluble epoxide hydrolase (sEH) deletion or its pharmacol. inhibition have been shown to have beneficial effects on inflammation, ischemia, hypertension and diabetes. Owing to the diverse role of EETs, current study was designed to evaluate the therapeutic potential of 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl) urea (TPPU), a novel sEHI against fructose-induced diabetes and related complications in rats. Sprague-Dawley rats (200 – 230 g) were divided into four different groups, each containing 10 animals. One group served as a normal control and received standard diet and drinking water. The second group served as a diseased control and received standard diet, 25% fructose in drinking water and was treated with vehicle only. The third and fourth groups received standard diet, 25% fructose in drinking water and TPPU (2 mg/kg) or metformin (150 mg/kg), resp. All treatments were given orally for 12 wk. At the end of the study, blood samples were collected to measure serum insulin levels and other biochem. parameters. Animals were dissected to collect tissue specimens for histol. and immunohistochem. anal. Animals fed on fructose and treated with vehicle demonstrated elevated blood insulin and glucose levels as well as high levels (P < 0.001) of triglycerides (TGs), cholesterol, low-d. lipoprotein (LDL) and homeostatic model assessment of insulin resistance (HOMA-IR) compared to naive rats. Similarly, the levels of alk. phosphatase (ALP), alanine aminotransferase (ALT), urea and uric acid were significantly (P < 0.001) increased in vehicle treated fructose fed animals. TPPU (2 mg/kg p.o.) and simultaneously fed on fructose for 12 wk substantially decreased HOMA-IR levels, lowered blood glucose, serum cholesterol, LDLs and TGs while high-d. lipoproteins (HDL) levels were increased compared to untreated animals. Metformin, a standard reference drug showed similar results. Microscopic studies of liver and pancreatic sections of TPPU treated animals showed marked improvement in cellular architecture compared to untreated animals. Current study demonstrated profound therapeutic potential of TPPU against fructose induced-diabetes and related metabolic complications which was evident by its attenuating effect fructose-induced hyperglycemia, hyperlipidemia and impaired renal and hepatic serum markers. This study involved multiple reactions and reactants, such as 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7Name: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea).

1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7) belongs to piperidine derivatives. The piperidine structural motif is present in numerous natural alkaloids. These include piperine, which gives black pepper its spicy taste. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising α-glucosidase inhibitors. The former are analogs of DNJ with an improved α-glucosidase inhibitory profile than that of DNJ. Boisson et al.Name: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Stromberga, Zane et al. published their research in Scientific Reports in 2020 | CAS: 83799-24-0

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Alterations in histamine responses between juvenile and adult urinary bladder urothelium, lamina propria and detrusor tissues was written by Stromberga, Zane;Chess-Williams, Russ;Moro, Christian. And the article was included in Scientific Reports in 2020.Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Inflammatory mediators may have a role in various lower urinary tract disorders. Histamine is known to induce significant increases in both the tension and frequency of spontaneous phasic contractions in both urothelium with lamina propria (U&LP) and detrusor muscle via the activation of H1 receptor in juvenile animal models. However, it is unclear whether age affects these contractile responses to histamine. This study assessed the histamine receptor subtypes mediating contraction in juvenile and adult porcine bladders and compared the urothelium with lamina propria and detrusor responses to histamine. Isolated tissue bath studies were conducted using strips of porcine U&LP and detrusor obtained from juvenile (6 mo) and adult (3 years) animals exposed to histamine receptor agonists and antagonists. Treatment with histamine (100μM) in U&LP of juvenile animals caused increases in baseline tension by 47.84 ± 6.52 mN/g (p < 0.001, n = 51) and by 50.76 ± 4.10 mN/g (p < 0.001, n = 55) in adult animals. Furthermore, the frequency of spontaneous phasic contractions was significantly enhanced in response to histamine in U&LP of both juvenile and adult tissues (p < 0.001 for both age groups). Treatment with an H2 agonist in U&LP of juvenile animals decreased baseline tension by 13.97 ± 3.45 mN/g (n = 12, p < 0.05), but had no effect in adult animals. Inhibition of H1 receptors resulted in significantly reduced contractile responses of U&LP and detrusor to histamine in both juvenile and adult animals (p < 0.05). Treatment with an H2 receptor antagonist significantly enhanced contractions in juvenile preparations (n = 10, p < 0.05) but had no effect in adult preparations (n = 8). In detrusor, treatment with histamine (100μM) in juvenile tissues showed a significantly higher increase in baseline tension of 19.10 ± 4.92 mN/g (n = 51) when compared to adult tissues exhibiting increases of 8.21 ± 0.89 mN/g (n = 56, p < 0.05). The increases in the baseline tension were significantly inhibited by the presence of H1 receptor antagonists in both juvenile and adult detrusor preparations Treatment with either the H2 receptor antagonist or agonist in detrusor had no effect on both juvenile and adult tissues. Therefore, the histamine receptor system may play an essential role in the maintenance of bladder function or in bladder dysfunction observed in some lower urinary tract disorders. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Recommanded Product: 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Shen, Yijun et al. published their research in Brain, Behavior, and Immunity in 2019 | CAS: 1222780-33-7

1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising α-glucosidase inhibitors. The former are analogs of DNJ with an improved α-glucosidase inhibitory profile than that of DNJ. Boisson et al.Recommanded Product: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea

Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model was written by Shen, Yijun;Peng, Weifeng;Chen, Qinglan;Hammock, Bruce D.;Liu, Junyan;Li, Dongyang;Yang, Jun;Ding, Jing;Wang, Xin. And the article was included in Brain, Behavior, and Immunity in 2019.Recommanded Product: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea The following contents are mentioned in the article:

This study aimed to investigate whether 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor with anti-inflammatory effects, could alleviate spontaneous recurrent seizures (SRS) and epilepsy-associated depressive behaviors in the lithium chloride (LiCl)-pilocarpine-induced post-status epilepticus (SE) rat model. The rats were i.p. (IP) injected with LiCl (127 mg/kg) and pilocarpine (40 mg/kg) to induce SE. A video surveillance system was used to monitor SRS in the post-SE model for 6 wk (from the onset of the 2nd week to the end of the 7th week after SE induction). TPPU (0.1 mg/kg/d) was intragastrically given for 4 wk from the 21st day after SE induction in the SRS + 0.1 TPPU group. The SRS + PEG 400 group was given the vehicle (40% polyethylene glycol 400) instead, and the control group was given LiCl and PEG 400 but not pilocarpine. The sucrose preference test (SPT) and forced swim test (FST) were conducted to evaluate the depression-like behaviors of rats. Immunofluorescent staining, ELISA, and western blot anal. were performed to measure astrocytic and microglial gliosis, neuronal loss, and levels of soluble epoxide hydrolase (sEH), cytokines [tumor necrosis factor alpha (TNF-α), interleukin (IL)-1β, and IL-6], and cyclic adenosine monophosphate (cAMP)-response element binding protein (CREB). The frequency of SRS was significantly decreased at 6 wk and 7 wk after SE induction in the 0.1TPP U group compared with the SRS + PEG 400 group. The immobility time (IMT) evaluated by FST was significantly decreased, whereas the climbing time (CMT) was increased, and the sucrose preference rate (SPR) evaluated by SPT was in an increasing trend. The levels of sEH, TNF-α, IL-1β, and IL-6 in the hippocampus (Hip) and prefrontal cortex (PFC) were all significantly increased in the SRS + PEG 400 group compared with the control group; neuronal loss, astrogliosis, and microglial activation were also observed The astrocytic and microglial activation and levels of the pro-inflammatory cytokines in the Hip and PFC were significantly attenuated in the TPPU group compared with the SRS + PEG 400 group; moreover, neuronal loss and the decreased CREB expression were significantly alleviated as well. TPPU treatment after SE attenuates SRS and epilepsy-associated depressive behaviors in the LiCl-pilocarpine induced post-SE rat model, and it also exerts anti-inflammatory effects in the brain. Our findings suggest a new therapeutic approach for epilepsy and its comorbidities, especially depression. This study involved multiple reactions and reactants, such as 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7Recommanded Product: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea).

1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. The piperidine and polyhydroxylated indolizidine derivatives have shown to be promising α-glucosidase inhibitors. The former are analogs of DNJ with an improved α-glucosidase inhibitory profile than that of DNJ. Boisson et al.Recommanded Product: 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Carnovale, Carla et al. published their research in World Allergy Organization Journal in 2022 | CAS: 83799-24-0

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. The piperidine ring can be found not only in more than half of the currently known structures of alkaloids, but also in many natural or synthetic compounds with interesting biological activities. Piperidine prefers a chair conformation, similar to cyclohexane. Unlike cyclohexane, piperidine has two distinguishable chair conformations: one with the N–H bond in an axial position, and the other in an equatorial position.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Safety of fexofenadine and other second-generation oral antihistamines before and after the removal of the prescription requirement in Italy and other European countries: A real-world evidence study and systematicreview was written by Carnovale, Carla;Battini, Vera;Gringeri, Michele;Volonte, Marina;Uboldi, Maria Chiara;Chiarenza, Andrea;Passalacqua, Giovanni. And the article was included in World Allergy Organization Journal in 2022.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

The change from prescription to over-the-counter (OTC) status of oral antihistamines may raise concerns about drug safety due to the possibility of misuse/abuse. In most European countries, oral antihistamines are available without prescription, whereas in Italy, only <10-tablet packs are available OTC. To evaluate the safety profile of fexofenadine after OTC switch in Italy in a real-world setting, and to compare its safety profile to that of other European countries where larger pack sizes are available. To compare the safety of fexofenadine, cetirizine, and loratadine in Italy. To examine safety/efficacy across Europe with a systematic review. This case-by-case anal. used the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) to extract data of the adverse events (AEs) related to fexofenadine, loratadine and cetirizine in Italy Jan. 2010-June 2020. The year 2016 was taken as the index date (removal of prescription requirement) for evaluation of the reporting trend of AEs of fexofenadine in Italy and make a comparison pre/post-OTC switch. A comparison of AEs with other European countries where fexofenadine is sold OTC in large packs >20 tablets (Belgium, Portugal, Switzerland, Finland, Hungary) was made. The rate at which an AE related to oral antihistamines occurred was estimated by calculation of the reporting rate (number of cases/[defined daily dose/1000 inhabitants per day]) on the basis of IQVIA sales data using the Italian Institute of Statistics database. A systematic review of the literature was also performed. There were 3760 reports of AEs with a suspected association with fexofenadine; of these, eight were reported from Italy. There was a slightly increasing trend per yr, in line with a general reporting trend of other drugs. In European countries where fexofenadine is available, the impact of OTC switch on AE reporting activity was negligible: from 2016, the reporting rate increased slightly and then normalized at 3.01, an incidence value similar to that recorded before the OTC switch (3.7 in 2015). Of 22 studies included in the systematic review, 18 (82%) pos. evaluated the OTC use of oral antihistamines, confirming an acceptable safety/tolerability profile. There was no difference in number of AEs reported for fexofenadine pre/post-OTC switch, indicating a similar safety profile. Spontaneous reporting systems are a valuable source of real-world data and support the OTC provision of oral antihistamines in Europe and fexofenadine in Italy, in addition to supporting the use of larger pack sizes in Italy. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. The piperidine ring can be found not only in more than half of the currently known structures of alkaloids, but also in many natural or synthetic compounds with interesting biological activities. Piperidine prefers a chair conformation, similar to cyclohexane. Unlike cyclohexane, piperidine has two distinguishable chair conformations: one with the N–H bond in an axial position, and the other in an equatorial position.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Karki, Santosh et al. published their research in Rapid Communications in Mass Spectrometry in 2021 | CAS: 83799-24-0

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Several piperidine alkaloids isolated from natural herbs, were found to exhibit antiproliferation and antimetastatic effects on various types of cancers both in vitro and in vivo for example Piperine, Evodiamine, Matrine, Berberine and Tetrandine.Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Development of a robotics platform for automated multi-ionization mass spectrometry was written by Karki, Santosh;Meher, Anil K.;Inutan, Ellen D.;Pophristic, Milan;Marshall, Darrell D.;Rackers, Kevin;Trimpin, Sarah;McEwen, Charles N.. And the article was included in Rapid Communications in Mass Spectrometry in 2021.Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Successful coupling of a multi-ionization automated platform with com. available mass spectrometers provides improved coverage of compounds in complex mixtures through implementation of new and traditional ionization methods. The versatility of the automated platform is demonstrated through coupling with mass spectrometers from two different vendors. Standards and complex biol. samples were acquired using electrospray ionization (ESI), solvent-assisted ionization (SAI) and matrix-assisted ionization (MAI). The MS® prototype automated platform samples from 96- or 384-well plates as well as surfaces. The platform interfaces with Thermo Fisher Scientific mass spectrometers by replacement of the IonMax source, and on Waters mass spectrometers with addnl. minor source inlet modifications. The sample is transferred to the ionization region using a fused-silica or metal capillary which is cleaned between acquisitions using solvents. For ESI and SAI, typically 1μL of sample solution is drawn into the capillary tube and for ESI slowly dispensed near the inlet of the mass spectrometer with voltage placed on the delivering syringe barrel to which the tubing is attached, while for SAI the sample delivery tubing inserts into the inlet without the need for high voltage. For MAI, typically, 0.2μL of matrix solution is drawn into the syringe before drawing 0.1μL of the sample solution and dispensing to dry before insertion into the inlet. A comparison study of a mixture of angiotensin I, verapamil, crystal violet, and atrazine representative of peptides, drugs, dyes, and herbicides using SAI, MAI, and ESI shows large differences in ionization efficiency of the various components. Solutions of a mixture of erythromycin and azithromycin in wells of a 384-microtiter well plate were mass analyzed at the rate of ∼1 min per sample using MAI and ESI. The authors report the anal. of bacterial extracts using automated MAI and ESI methods. Finally, the ability to perform surface anal. with the automated platform is also demonstrated by directly analyzing dyes separated on a thin-layer chromatog. (TLC) plate and compounds extracted from the surface of a beef liver tissue section. The prototype multi-ionization automated platform offers solid matrix introduction used with MAI, as well as solution introduction using either ESI or SAI. The combination of ionization methods extends the types of compounds which are efficiently ionized and is especially valuable with complex mixtures as demonstrated for bacterial extracts While coupling of the automated multi-ionization platform to Thermo and Waters mass spectrometers is demonstrated, it should be possible to interface it with most com. mass spectrometers. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Several piperidine alkaloids isolated from natural herbs, were found to exhibit antiproliferation and antimetastatic effects on various types of cancers both in vitro and in vivo for example Piperine, Evodiamine, Matrine, Berberine and Tetrandine.Safety of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Hinnenkamp, Vanessa et al. published their research in Analytical and Bioanalytical Chemistry in 2022 | CAS: 83799-24-0

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Industrially, piperidine is produced by the hydrogenation of pyridine, usually over a molybdenum disulfide catalyst. Pyridine can also be reduced to piperidine via a modified Birch reduction using sodium in ethanol.Computed Properties of C32H39NO4

Target, suspect and non-target screening analysis from wastewater treatment plant effluents to drinking water using collision cross section values as additional identification criterion was written by Hinnenkamp, Vanessa;Balsaa, Peter;Schmidt, Torsten C.. And the article was included in Analytical and Bioanalytical Chemistry in 2022.Computed Properties of C32H39NO4 The following contents are mentioned in the article:

The anthropogenic entry of organic micropollutants into the aquatic environment leads to a potential risk for drinking water resources and the drinking water itself. Therefore, sensitive screening anal. methods are needed to monitor the raw and drinking water quality continuously. Non-target screening anal. has been shown to allow for a more comprehensive investigation of drinking water processes compared to target anal. alone. However, non-target screening is challenging due to the many features that can be detected. Thus, data processing techniques to reduce the high number of features are necessary, and prioritization techniques are important to find the features of interest for identification, as identification of unknown substances is challenging as well. In this study, a drinking water production process, where drinking water is supplied by a water reservoir, was investigated. Since the water reservoir provides surface water, which is anthropogenically influenced by wastewater treatment plant (WWTP) effluents, substances originating from WWTP effluents and reaching the drinking water were investigated, because this indicates that they cannot be removed by the drinking water production process. For this purpose, ultra-performance liquid chromatog. coupled with an ion-mobility high-resolution mass spectrometer (UPLC-IM-HRMS) was used in a combined approach including target, suspect and non-target screening anal. to identify known and unknown substances. Addnl., the role of ion-mobility-derived collision cross sections (CCS) in identification is discussed. To that end, six samples (two WWTP effluent samples, a surface water sample that received the effluents, a raw water sample from a downstream water reservoir, a process sample and the drinking water) were analyzed. Pos. findings for a total of 60 substances in at least one sample were obtained through quant. screening. Sixty-five percent (15 out of 23) of the identified substances in the drinking water sample were pharmaceuticals and transformation products of pharmaceuticals. Using suspect screening, further 33 substances were tentatively identified in one or more samples, where for 19 of these substances, CCS values could be compared with CCS values from the literature, which supported the tentative identification. Eight substances were identified by reference standards In the non-target screening, a total of ten features detected in all six samples were prioritized, whereby metoprolol acid/atenolol acid (a transformation product of the two β-blockers metoprolol and atenolol) and 1,3-benzothiazol-2-sulfonic acid (a transformation product of the vulcanization accelerator 2-mercaptobenzothiazole) were identified with reference standards Overall, this study demonstrates the added value of a comprehensive water monitoring approach based on UPLC-IM-HRMS anal. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Computed Properties of C32H39NO4).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine has a role as a reagent, a protic solvent, a base, a catalyst, a plant metabolite, a human metabolite and a non-polar solvent. Industrially, piperidine is produced by the hydrogenation of pyridine, usually over a molybdenum disulfide catalyst. Pyridine can also be reduced to piperidine via a modified Birch reduction using sodium in ethanol.Computed Properties of C32H39NO4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Saraswathi Pravallika, M. et al. published their research in European Journal of Biomedical and Pharmaceutical Sciences in 2021 | CAS: 83799-24-0

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Electric Literature of C32H39NO4

A study on prescription pattern of chronic kidney disease in tertiary care hospital was written by Saraswathi Pravallika, M.;Sampreethi, H.;Anusha, C. H.;Rohini, K.;Shete, Shivkumar. And the article was included in European Journal of Biomedical and Pharmaceutical Sciences in 2021.Electric Literature of C32H39NO4 The following contents are mentioned in the article:

The aim of the present investigation is to study the prescription pattern of chronic kidney disease in tertiary care hospital. The objective of the study was to study the prescription patterns of drugs used in chronic kidney disease and other comorbid conditions and to identify which drug is mostly prescribed at that hospital. To assess the rationality of prescription. To evaluate the medication adherence in CKD patients. The study on prescribing pattern definitely improves the quality of prescription writing, so study of drug prescribing pattern is relevant in the present scenario. To evaluate the prevalence of correct dosing in chronic kidney diseases depending on renal function estimation This is a retrospective, prospective observational study conducted over a period of six months. The study was conducted at Medicine ward of GLENEAGLES AWARE GLOBAL HOSPITAL LB.NAGAR. Patients who admitted to Nephrol. department of the hospital during a six- month period from Oct. 2021 to March 2021 are enrolled. CKD patients visiting the nephrologists are evaluated, diagnosed and prescribed with suitable therapy. All necessary details were collected from patient demographics, prescription chart, lab data, progress chart, medical records, doctor’s notes, nursing notes using a suitable designed data collection form. One hundred one patients were included in the project; with a mean age of 62.5. ± 18 years. More than half of patients were male, 77(76.2%). The mean BMI was 26 ± 1.15 kg/ m2. The majority of patients were having normal weight 80 (79.2%), 15 (14.8%) patients had overweight, and obesity and only 6 (5.9%) patients were underweight. While 35 (34.6%) patients were smokers, 10 (9.9%) were ex-smokers and 56 (55.4%) patients were non- smokers. Anti- hypertensive agents are predominantly used among the patients. The most preferred options were beta blockers, calcium channel blockers and diuretics. Most of the physicians prescribed metoprolol (18.2%), amlodipine (38.3%), and cilnidipine (2%). Diuretics were the preferred option by the physician furosemide (92.3%), anti-platelets that are prescribed by the physicians are Aspirin (69.2%), clopidogrel (30.7%). Among the lipid lowering agents, atorvastatin (92.8%) was given to the most of the patients. sulbactam (20.4%), cefoperazone (20.4%), clarithromycin (10.25%), amoxycillin (10.25%) were mostly prescribed antibiotics in the study. The study concluded that most of the patients included in the study were suffering from chronic kidney disease. These may be due to their food habits, smoking, less exercise and poor health hygiene. The maximum number of patients was male; it may be due to smoking and alc. habits. Comorbidities such as hypertension, hyperglycemia, albuminuria, renal structure, and sex hormones, have been reported to have different effects on males and females. Thus, CKD progression may differ depending on sex. Early recognition with timely initiation of treatment in collaboration with nephrologists will improve the care for CKD patients. Thus, physicians and Nephrologists play an important outcome in patients with CKD. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Electric Literature of C32H39NO4).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Electric Literature of C32H39NO4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Priyanki et al. published their research in World Journal of Pharmacy and Pharmaceutical Sciences in 2021 | CAS: 83799-24-0

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Evaluation of efficacy of Levocetrizine, Fexofenadine and their combination with monteleukast in allergic rhinitis in Jharkhand, India was written by Priyanki;Kumar, Pramveer;Kumari, Kusum;Ragini, Kavita;Chandra, Satish;Kumar, Sandeep;Gari, Manju. And the article was included in World Journal of Pharmacy and Pharmaceutical Sciences in 2021.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Allergic Rhinitis is the most common of all atopic diseases. It is an important public health problem. It affects 20-25% of world population. The most common pharmacol. treatment options include intranasal corticosteroids, antihistamines, Leukotriene (LT) pathway inhibitor, α-adrenergic agonist, etc. Here, we aim to compare the efficacy of Levocetrizine and Fexofenadine and also, to compare the efficacy of Levocetrizine + Montelukast and fexofenadine + Montelukast in the treatment of allergic rhinitis in a tertiary hospital in Jharkhand, India. This observational follow up study was conducted in the department of pharmacol. & Therapeutics, among the patient attending out patient department of Ear, Nose and Throat (ENT) of Rajendra Institute of Medical Sciences, Ranchi, Jharkhand with prior approval from Institutional ethics committee. Observational, single centered, randomised, open label, four arm, parallel-group, comparative clin. study. 110 Patients were enrolled who have met the inclusion criteria for the study from the OPD of ENT Department of RIMS during the study period. The patients were placed in four groups and received their resp. medication orally once daily in the evening for period of two weeks. On the day of the participant enrolment, a written informed consent was taken from all the patient, medical history, phys. examination, patient′s symptoms recorded on TNSS Sheet (Total Nasal Symptoms Score) and demonstrated to subject how to note and hand over the TNSS Sheet. After Completion of study on 15th day, phys. examination and vital sign were checked; recording on sheet was collected. Mean changes in TNSS at the end of 24 h, 1st and 2nd week and comparison of effect of drugs with and without montelukast with the help of Total Nasal Score were calculated by using Statistical Package for the Social Sciences, IBM SPSS 20. The data was tabulated as mean ± standard deviation (Mean SD). Paired′t′ test was used to compare mean changes in TNSS Score before and after treatment. Out of total 110 enrolled patients, 98 completed the study, 4 patients not completed 2weeks treatment, 2 patients had change in disease pattern and 6 patient lost to follow up. The demog. characteristics of four groups were compared for age and sex. All groups had female predominance. The baseline Total Nasal Symtoms Score (TNSS) were comparable among the all four treatment groups. The mean TNSS was significantly reduced in all four study groups. After 1day of treatment change in TNSS have in following order Group C > Group D >Group A >Group B. Maximum change was observed in Levocetrizine & Montelukast combination group and min. change was observed in Fexofenadine group. Same order of change in TNSS was observed in study after 1 wk and 2weeks of treatment. So in our study Levocetrizine have been found better than fexofenadine in decreasing TNSS in allergic rhinitis patient. Similarly Levocetirizine-Montelukast combination decreases TNSS more than Fexofenadine-Montelukast combination. All the study drugs have shown significant improvement in quality of life of Allergic rhinitis patients. Levocetrizine has shown more effectiveness than Fexofenadine when used alone in allergic rhinitis patient. Levocetrizine-montelukast combination shows better effect than Fexofenadine-Montelukast combination drugs. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Buechel, Karl Heinz et al. published their research in Chemische Berichte in 1962 | CAS: 30727-21-0

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate

Acyl-lactone rearrangement. XXIII. Syntheses of cyclic amino acids by the reaction principle of the acyl-lactone rearrangement was written by Buechel, Karl Heinz;Korte, Friedhelm. And the article was included in Chemische Berichte in 1962.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate The following contents are mentioned in the article:

3-Ethoxalyl-2-pyrrolidones and 3-ethoxalyl-2-piperidones were converted by heating with decarboxylation and rearrangement and by subsequent catalytic hydrogenation to DL-hygrinic acid (I), DL-proline (II), and DL-N-methylpipecolinic acid (III), resp., in high yields. N-Methyl-2-pyrrolidone and (CO2Et)2 (IV) were condensed with coarsely cut and with powd. K to yield 56 and 60-65%, resp., 3-ethoxalyl-N-methyl-2-pyrrolidone (V). V (1 g.) in 25 cc. concentrated HCl refluxed 20 hrs., concentrated in vacuo, diluted with 20 cc. H2O, treated with 1 g. 2,4-(O2N)2C6H3NHNH2 in 170 cc. 2N HCl, and kept several days gave the 2,4-dinitrophenylhydrazone of MeNH(CH2)3-COCO2H, m. 183-4° (2N HCl). V (10 g.) in 60 cc. concentrated HCl refluxed 20 hrs. until the maximum at 285 mμ had disappeared, concentrated to 50 cc., cooled, filtered, from 0.1-0.3 g. V, diluted with H2O, hydrogenated over 0.5 g. PtO2, filtered, and evaporated, and the residual I.HCl (9 g.) dissolved in H2O, passed through weakly basic Duolite A 7, and evaporated gave I, m. 174-5° (EtOH-Et2O); I.HCl m. 183-5° (EtOH-Et2O). 2-Pyrrolidone heated with excess Ac2O gave 95% N-Ac derivative (VI), b12 109-10°. VI (127 g.) and 204 g. IV in 100 cc. dry Et2O added dropwise at -5 to 0° to 39.1 g. powd. K and 1 cc. absolute EtOH in 400 cc. dry Et2O, stirred 8 hrs., added with stirring and cooling to 500 cc. 2N HCl, and extracted with CHCl3 gave 209 g. (crude) 3-ethoxalyl-N-acetyl-2-pyrrolidone (VII), b0.05 90-5°, blue-violet with FeCl3; the higher boiling fractions deposited 3-ethoxalyl-2-pyrrolidone, m. 134-6° (ligroine), blue with FeCl3. Crude VII (5 g.) and 20 cc. 6N HCl heated 24 hrs. at 60° gave 1.2 g. 3-oxalyl-2-pyrrolidone, m. 208-10° (decomposition). VI (127 g.) and 180 g. IV added dropwise with stirring to 39.1 g. K and 1 cc. absolute EtOH in 400 cc. dry MePh at about 100° and worked up in the usual manner yielded 160 g. (crude) [EtO2C(CH2)3NHCO]2 (VIII), needles, m. 103-6° (ligroine, b. 80-110°). VIII refluxed with 6N HCl gave [HO2C-(CH2)3NHCO]2, m. 212°. The brown semisolid residue from the mother liquor from VIII treated in EtOH with C, concentrated, and diluted with petr. ether gave 26 g. 2,3-dioxo-4-carbethoxypiperidine, m. 148° (C6H6), ruby-red with FeCl3. VII (22.7 g.) in concentrated HCl refluxed 1 hr., concentrated to half-volume, diluted with an equal volume H2O, hydrogenated over 0.5 g. PtO2, and worked up, and the residual crude II.HCl dissolved in H2O, passed through Duolite A 7, eluted with 1.5 l. H2O, and evaporated yielded 9 g. II, m. 214-15°. VII treated in the usual manner with 2,4-(O2N)2C6H3NH-NH2 yielded the 2,4-dinitrophenylhydrazone of H2N(CH2)3-COCO2H, yellow, m. 217-18° (2N HCl). α-Ethoxalyl-N-methyl-2-piperidone (21.3 g.) added to 100 cc. boiling 6N HCl, refluxed about 5 min., concentrated to about 40 cc., diluted with an equal volume H2O, hydrogenated over 0.5 g. PtO2, and worked up yielded 17.9 g. III.HCl, m. 195-200°. III.HCl in H2O treated with Amberlite 4-B and evaporated gave 14.0 g. III, m. 208-10° (EtOH-Et2O). III treated in the usual manner with 2,4-(O2N)2C6H3-NHNH2 gave the 2,4-dinitrophenylhydrazone of MeNH(CH2)4-COCO2H, yellow needles, m. 207° (2N HCl). III (2.9 g.) in MeOH methylated with MeI-Ag2O yielded DL-homostachydrine (IX), very hygroscopic crystals, m. 207-8° (EtOH-Et2O); IX.-HCl, m. 211° (EtOH-Et2O). This study involved multiple reactions and reactants, such as Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0Name: Ethyl 2,3-dioxopiperidine-4-carboxylate).

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

 

Hasse, Kurt et al. published their research in Chemische Berichte in 1960 | CAS: 30727-21-0

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.HPLC of Formula: 30727-21-0

Preparation of Δ1-pyrroline-2-carboxylic acid and a new proline synthesis was written by Hasse, Kurt;Wieland, Alfred. And the article was included in Chemische Berichte in 1960.HPLC of Formula: 30727-21-0 The following contents are mentioned in the article:

2,3-Dioxopiperidine-4-carboxylic acid Et ester (I), obtained by condensation of 2-pyrrolidone (II) with (CO2Et)2 (III), was converted by hydrolysis to H2N(CH2)3COCO2H.HCl (IV) and this hydrogenated to yield DL-proline (V). K (10 g.) dissolved in 100 cc. absolute EtOH, the solution evaporated in vacuo, the residue dissolved in 200 cc. Et2O, the solution treated with 25 cc. II and 50 cc. III in 50 cc. Et2O, the mixture treated after 24 hrs. with 100 cc. 1:4 HCl, and the Et2O phase concentrated gave 90% [EtO2C(CH2)3NHCO]2 (VI), m. 106° (H2O or EtOH). VI (1 g.) in 5 cc. 6N HCl heated 1 hr. at 80° and concentrated gave [HO2C(CH2)3NHCO]2, m. 210°. II condensed in the usual manner with III, the mixture acidified with HCl, and the Et2O phase evaporated in vacuo at 120° gave 3-ethoxalyl-2-pyrrolidone (VII), m. 132° (EtOH). 3-Oxalyl-2-pyrrolidone (VIII) (0.75 g.) and 20 cc. alc. HCl kept 36 hrs. at room temperature and evaporated in vacuo yielded VII, m. 131-2° (C6H6). VII (0.5 g.) in 5 cc. 6N HCl heated 0.5 hr. at 80° gave VIII, decomposing above 205°. K (4 g.) under 60 cc. Et2O treated during 1 hr. with 13.8 g. absolute EtOH, warmed 3-4 hrs. on the water bath, treated at 0-5° with stirring with 14.6 g. III, the mixture treated after 10 min. during 0.5 hr. with 18.9 g. N-benzoyl-2-pyrrolidone in 27 cc. dry dioxane, diluted after 1 hr. with 150 cc. Et2O, and filtered after 12 hrs., the residue dried in vacuo (23 g.), added with stirring to 40 cc. H2O, 15 cc. HCl, and 30 cc. CHCl3, the CHCl3 phase evaporated, the residual oil dissolved at 90° with stirring during 10 min. in 40 cc. 6N HCl, and the hot solution filtered and cooled gave 2 g. VIII, needles, decomposing above 205° with sintering; the mother liquor gave 5.6 g. HO2CCONH(CH2)3CO2H, m. 163-4° (decomposition) (H2O or Me2CO). VIII (20.4 mg.) in 10 cc. H2O treated with 15 cc. 1% 2,4-(O2N)2C6H3NHNH2 in 2N HCl gave the 2,4-dinitrophenylhydrazone of VIII, m. 221° (decomposition). K (20 g.), a few crystals of iodine and a small amount of Hg2Cl2 in 50 cc. absolute C6H6 treated with 40 cc. absolute EtOH in portions, the mixture diluted with 30 cc. EtOH in 150 cc. C6H6, warmed slightly, diluted further with 300 cc. C6H6, treated with 43 g. II and 73 g. III, refluxed 18 hrs. with stirring, and treated with 80 cc. 6N HCl, the hot C6H6 layer decanted, the aqueous phase extracted with C6H6, and the combined C6H6 solutions worked up yielded 80% I, m. 148°. I (370 mg.) in EtOH hydrogenated at 20°/760 mm. over PtO2, filtered, and evaporated gave 3-hydroxy-4-carbethoxy-2-piperidone, m. 121-2° (C6H6). I (5.3 g.) and 80 cc. 6N HCl refluxed 6 min. (in larger runs 20 min.) and evaporated at 35°/12 mm., and the residue refrigerated several hrs., filtered, washed with cold HCl, and dried yielded IV, m. 113° (HCl-AcOH-Et2O). VIII (1.03 g.) and 35 cc. 6N HCl refluxed 1 hr. and evaporated at 35°/16 mm., the residue dissolved in H2O and chromatographed on Dowex 50-X-8 (H form), and the fractions from 207-358 cc. evaporated gave 0.7 g. IV, m. 113° (decomposition). IV (48.7 mg.) hydrogenated 3 hrs. at 21°/755 mm. over PtO2, filtered, treated with Ag2O and then H2S, refiltered, and evaporated, and the residue and 48 mg. picric acid dissolved in hot glacial AcOH and diluted with Et2O gave the picrate of V, m. 134-5°. I (12.5 g.) and 200 cc. 6N HCl refluxed 7 min., concentrated at 40°/25 mm. to 30 cc., diluted with 120 cc. H2O, hydrogenated 5 hrs. at 25°/1 atm. over 270 mg. PtO2, filtered, placed on Amberlite IR-4B, washed with 1.3 l. H2O, and eluted gave 5.51 g. pure V. This study involved multiple reactions and reactants, such as Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0HPLC of Formula: 30727-21-0).

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.HPLC of Formula: 30727-21-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem